Point72 Asset Management
AARD

Point72 Asset Management’s Aardvark Therapeutics AARD Stock Holding History

Point72 Asset Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Buy
+22,872
New +$107K ﹤0.01% 3649
2026
Q1 		– Sell
-36,922
Closed -$485K – 4673
2025
Q4 		$485K Buy
+36,922
New +$461K ﹤0.01% 3247

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Point72 Asset Management's AARD Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 22,872 shares worth $132K. The stake represents ﹤0.01% of the portfolio and ranks #3649 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in AARD as recently as Q4 2025.

Point72 Asset Management first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $485K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Point72 Asset Management held 22,872 shares of Aardvark Therapeutics worth $132K as of Q2 2026.
  • Aardvark Therapeutics was a new Point72 Asset Management position in Q2 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3649 holding.
  • Point72 Asset Management first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Point72 Asset Management's Aardvark Therapeutics position peaked at $485K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.